EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk

Jennifer La, Omid Jafari, Kaelyn Nannini, Nhan V Do, Mary T Brophy, Nathanael R Fillmore, Ang Li

Research and Practice in Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.rpth.2026.106830 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Research and Practice in Thrombosis and Haemostasis, 2026. Verfasst von Jennifer La und 6 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Electronic Health Records, Neoplasms, Hemorrhage, Venous Thromboembolism. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The electronic health record cancer-associated thrombosis (EHR-CAT) model was derived to predict cancer-associated venous thromboembolism (VTE). Prior validations often relied on cancer registry data with reporting delays.

Objectives

We aimed to perform an external temporal validation of the EHR-CAT model among patients at low risk of bleeding using contemporary Veterans Affairs electronic health record data.

Methods

We conducted a retrospective cohort study in patients with active cancer who received systemic therapy within the national Veterans Affairs (VA) health care system from 2017 to 2024. The key inclusion criteria included: (1) having readily extractable data for EHR-CAT calculation without cancer registry data, (2) index date at first or subsequent lines of therapy, (3) exclusion of adjuvant endocrine monotherapy with low risk for VTE, and (4) application of anticoagulant clinical trial exclusion criteria to minimize bleeding risk. Patients from previously published studies were excluded. Systemic therapies were defined using the VA Corporate Data Warehouse, and one line was randomly selected. VTE outcomes were determined using validated VTE-Bidirectional Encoder Representations from Transformers natural language processing from clinical notes. Time-dependent C-statistic and calibration slope were assessed.

Results

Among 65,341 patients with cancer receiving systemic therapy (42,865 first-line and 22,476 second-line or higher), median age was 71.9 years, and 95% were male. Most common cancers included prostate (16.1%), lung (14.8%), lymphoma (11.5%), and bladder (11.1%). The VTE incidence at 6 months was 5.4%. VTE was observed in 1.9%, 4.0%, 4.7%, 6.5%, 9.6%, and 12.3% of patients with EHR-CAT scores 0-, 1, 2, 3, 4, and 5+, respectively (C-statistic 0.67). Calibration slope was 0.876.

Conclusion

The EHR-CAT model, when applied across different lines of therapy, demonstrated similar performance as in previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Electronic Health RecordsNeoplasmsHemorrhageVenous ThromboembolismHumansRetrospective StudiesMaleAgedFemaleMiddle AgedUnited StatesRisk FactorsUnited States Department of Veterans AffairsReproducibility of ResultsRisk AssessmentTime Factors

Stichwörter der Autor:innen

neoplasmsprediction algorithmsthromboemblismvalidation studyvenous thrombosis

Autor:innen und Institutionen

  • Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA.
  • Section of Hematology & Medical Oncology, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Veterans Affairs Boston Healthcare System, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • American Society of Hematology
  • Conquer Cancer Foundation
  • CPRIT
  • NIH
  • American Heart Association Inc

Zitieren

APA

La, J., Jafari, O., Nannini, K., Do, N. V., Brophy, M. T., Fillmore, N. R., & Li, A. (2026). Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk. Research and Practice in Thrombosis and Haemostasis. https://doi.org/10.1016/j.rpth.2026.106830

Vancouver

La J, Jafari O, Nannini K, Do NV, Brophy MT, Fillmore NR, et al. Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk. Research and Practice in Thrombosis and Haemostasis. 2026. doi:10.1016/j.rpth.2026.106830

BibTeX
@article{La2026,
  author = {La, Jennifer and Jafari, Omid and Nannini, Kaelyn and Do, Nhan V and Brophy, Mary T and Fillmore, Nathanael R and Li, Ang},
  title = {Temporal validation of the electronic health record cancer-associated thrombosis model in patients with low bleeding risk},
  journal = {Research and Practice in Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.rpth.2026.106830}
}
Kostenlos starten →